Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Lets thrive together
#Healthcare #MedTech #HealthInnovation #DoctorsOfLinkedIn #HealthIT To view or add a comment, sign in Phase 3 TRANSCEND: Setmelanotide achieved a 16.5% reduction in BMI over 52 weeks by directly activating MC4R and bypassing impaired leptinPOMC signalingmarking a significant advance for patients with acquired hypothalamic obesity
L-
J Hum Genet 55:565570
7 Following strong clinical trial results, higher-dose versions of Ozempic and Mounjaro, called Wegovy and Zepbound, respectively, have been approved for obesity by the FDA
US$ 22.34
US$ 29.72
US$ 26.63
